Search tips
Search criteria 


Logo of jmedgeneJournal of Medical GeneticsVisit this articleSubmit a manuscriptReceive email alertsContact usBMJ
J Med Genet. 2005 February; 42(2): 98–102.
PMCID: PMC1735984

Milroy disease and the VEGFR-3 mutation phenotype


Primary congenital lymphoedema (Milroy disease) is a rare autosomal dominant condition for which a major causative gene defect has recently been determined. Mutations in the vascular endothelial growth factor receptor 3 (VEGFR-3) gene have now been described in 13 families world-wide. This is a review of the condition based on the clinical findings in 71 subjects from 10 families. All 71 individuals have a mutation in VEGFR-3. Ninety per cent of the 71 individuals carrying a VEGFR-3 mutation showed signs of oedema, which was confined in all cases to the lower limbs. In all but two cases onset of swelling was from birth. Other symptoms and signs included cellulitis (20%), large calibre leg veins (23%), papillomatosis (10%), and upslanting toenails (10%). In males, hydrocoele was the next most common finding after oedema (37%). Thorough clinical examination of these patients indicates that there are few clinical signs in addition to lower limb oedema. Rigorous phenotyping of patients produces a high yield of VEGFR-3 mutations.

Full Text

The Full Text of this article is available as a PDF (156K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Mortimer PS. Managing lymphedema. Clin Dermatol. 1995 Sep-Oct;13(5):499–505. [PubMed]
  • Ferrell RE, Levinson KL, Esman JH, Kimak MA, Lawrence EC, Barmada MM, Finegold DN. Hereditary lymphedema: evidence for linkage and genetic heterogeneity. Hum Mol Genet. 1998 Dec;7(13):2073–2078. [PubMed]
  • Evans AL, Brice G, Sotirova V, Mortimer P, Beninson J, Burnand K, Rosbotham J, Child A, Sarfarazi M. Mapping of primary congenital lymphedema to the 5q35.3 region. Am J Hum Genet. 1999 Feb;64(2):547–555. [PubMed]
  • Karkkainen MJ, Ferrell RE, Lawrence EC, Kimak MA, Levinson KL, McTigue MA, Alitalo K, Finegold DN. Missense mutations interfere with VEGFR-3 signalling in primary lymphoedema. Nat Genet. 2000 Jun;25(2):153–159. [PubMed]
  • Irrthum A, Karkkainen MJ, Devriendt K, Alitalo K, Vikkula M. Congenital hereditary lymphedema caused by a mutation that inactivates VEGFR3 tyrosine kinase. Am J Hum Genet. 2000 Aug;67(2):295–301. [PubMed]
  • Karkkainen Marika J, Haiko Paula, Sainio Kirsi, Partanen Juha, Taipale Jussi, Petrova Tatiana V, Jeltsch Michael, Jackson David G, Talikka Marja, Rauvala Heikki, et al. Vascular endothelial growth factor C is required for sprouting of the first lymphatic vessels from embryonic veins. Nat Immunol. 2004 Jan;5(1):74–80. [PubMed]
  • Fang J, Dagenais SL, Erickson RP, Arlt MF, Glynn MW, Gorski JL, Seaver LH, Glover TW. Mutations in FOXC2 (MFH-1), a forkhead family transcription factor, are responsible for the hereditary lymphedema-distichiasis syndrome. Am J Hum Genet. 2000 Dec;67(6):1382–1388. [PubMed]
  • Bell R, Brice G, Child AH, Murday VA, Mansour S, Sandy CJ, Collin JR, Brady AF, Callen DF, Burnand K, et al. Analysis of lymphoedema-distichiasis families for FOXC2 mutations reveals small insertions and deletions throughout the gene. Hum Genet. 2001 Jun;108(6):546–551. [PubMed]
  • Brice G, Mansour S, Bell R, Collin JRO, Child AH, Brady AF, Sarfarazi M, Burnand KG, Jeffery S, Mortimer P, et al. Analysis of the phenotypic abnormalities in lymphoedema-distichiasis syndrome in 74 patients with FOXC2 mutations or linkage to 16q24. J Med Genet. 2002 Jul;39(7):478–483. [PMC free article] [PubMed]
  • Irrthum Alexandre, Devriendt Koenraad, Chitayat David, Matthijs Gert, Glade Conrad, Steijlen Peter M, Fryns Jean-Pierre, Van Steensel Maurice A M, Vikkula Miikka. Mutations in the transcription factor gene SOX18 underlie recessive and dominant forms of hypotrichosis-lymphedema-telangiectasia. Am J Hum Genet. 2003 Jun;72(6):1470–1478. [PubMed]
  • Holberg CJ, Erickson RP, Bernas MJ, Witte MH, Fultz KE, Andrade M, Witte CL. Segregation analyses and a genome-wide linkage search confirm genetic heterogeneity and suggest oligogenic inheritance in some Milroy congenital primary lymphedema families. Am J Med Genet. 2001 Feb 1;98(4):303–312. [PubMed]
  • Evans AL, Bell R, Brice G, Comeglio P, Lipede C, Jeffery S, Mortimer P, Sarfarazi M, Child AH. Identification of eight novel VEGFR-3 mutations in families with primary congenital lymphoedema. J Med Genet. 2003 Sep;40(9):697–703. [PMC free article] [PubMed]
  • Levinson Kara L, Feingold Eleanor, Ferrell Robert E, Glover Thomas W, Traboulsi Elias I, Finegold David N. Age of onset in hereditary lymphedema. J Pediatr. 2003 Jun;142(6):704–708. [PubMed]
  • Dumont DJ, Jussila L, Taipale J, Lymboussaki A, Mustonen T, Pajusola K, Breitman M, Alitalo K. Cardiovascular failure in mouse embryos deficient in VEGF receptor-3. Science. 1998 Oct 30;282(5390):946–949. [PubMed]
  • Mäkinen T, Jussila L, Veikkola T, Karpanen T, Kettunen MI, Pulkkanen KJ, Kauppinen R, Jackson DG, Kubo H, Nishikawa S, et al. Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor-3. Nat Med. 2001 Feb;7(2):199–205. [PubMed]
  • Bollinger A, Isenring G, Franzeck UK, Brunner U. Aplasia of superficial lymphatic capillaries in hereditary and connatal lymphedema (Milroy's disease). Lymphology. 1983 Mar;16(1):27–30. [PubMed]
  • Saaristo Anne, Veikkola Tanja, Tammela Tuomas, Enholm Berndt, Karkkainen Marika J, Pajusola Katri, Bueler Hansruedi, Ylä-Herttuala Seppo, Alitalo Kari. Lymphangiogenic gene therapy with minimal blood vascular side effects. J Exp Med. 2002 Sep 16;196(6):719–730. [PMC free article] [PubMed]
  • Yoon Young-Sup, Murayama Toshinori, Gravereaux Edwin, Tkebuchava Tengiz, Silver Marcy, Curry Cynthia, Wecker Andrea, Kirchmair Rudolf, Hu Chun Song, Kearney Marianne, et al. VEGF-C gene therapy augments postnatal lymphangiogenesis and ameliorates secondary lymphedema. J Clin Invest. 2003 Mar;111(5):717–725. [PMC free article] [PubMed]

Articles from Journal of Medical Genetics are provided here courtesy of BMJ Publishing Group